A Global,Phase 2,Randomized,Double-Blind,Placebo-Controlled,Response-Adaptive Dose-Ranging Study of BMS-986177,anOralFactorXIa Inhibitor,for the PreventionofNewIschemi Stroke or New Silent Brain Infarction in Patients ReceivingAspirin and clopidogre
Clinical Trial Grant
Administered By
Neurology, Stroke and Vascular Neurology
Awarded By
Bristol-Myers Squibb Company
Start Date
June 3, 2019
End Date
November 22, 2021
Administered By
Neurology, Stroke and Vascular Neurology
Awarded By
Bristol-Myers Squibb Company
Start Date
June 3, 2019
End Date
November 22, 2021